Vera Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vera Therapeutics, Inc. on December 9, 2025. The report details a follow-on public offering of Class A common stock. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol "VERA."
Key Financial Metrics
The filing discloses the following capital raise metrics:
- Shares Issued: 6,138,108 shares of Class A common stock.
- Offering Price: $42.50 per share.
- Gross Proceeds: Approximately $260.9 million (before underwriting discounts and expenses).
- Over-Allotment Option: Underwriters were granted an option to purchase up to 920,716 additional shares, which was exercised in full on December 10, 2025.
- Closing Date: Expected on December 11, 2025.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the significant increase in equity capital through the public offering. The full exercise of the over-allotment option increases the total shares sold beyond the initial 6,138,108 shares.
Guidance, Outlook, and Risks
Management commentary is limited to the execution of the offering. The filing includes standard forward-looking statements regarding the completion of the offering and expected proceeds. Risks cited include market conditions, satisfaction of closing conditions, and macroeconomic or geopolitical events. The company disclaims any obligation to update these statements.
Investor Verification Checklist
- Confirm the final closing date of December 11, 2025, and the receipt of net proceeds after underwriting discounts.
- Verify the total number of shares outstanding post-offering, including the 920,716 shares from the exercised over-allotment.
- Review the prospectus supplement (File No. 333-282861) for specific details on the use of proceeds.
- Check subsequent filings for any updates on the satisfaction of closing conditions.